NeueHealth Inc (NEUE) AI Stock Analysis

• Market Cap: $60.64M
• Dividend Yield: N/A
• Average Volume (3M): 4.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: -13.83%
• EPS Growth: 87.09%
• Country: US
• Employees: 986
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Equipment & Services
• EPS (TTM): -1.68
• Shares Outstanding: 9,024,240
• 10 Day Avg. Volume: 3,400
• 30 Day Avg. Volume: 4,409
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 20.64
• Enterprise Value/Revenue: 1.38
• Enterprise Value/Gross Profit: 6.22
• Enterprise Value/Ebitda: -12.89
• 1Y Price Target: $6.50
• Price Target Upside: -3.27% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: $6.50 ▼(-3.27% Downside)

NeueHealth Inc's overall stock score is primarily impacted by its poor financial performance, characterized by high leverage and negative cash flows. While the earnings call provided some positive insights into consumer growth and profitability, the technical analysis and valuation metrics remain weak, reflecting ongoing challenges.

NeueHealth Inc Business Overview & Revenue Model

Company Description

NeueHealth, Inc., a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics. It operates risk-bearing clinics under the Centrum Health, AssociatesMD, and Premier Medical Associates brand names. The company also offers integrated system care solution, such as embedded pharmacy, laboratory, radiology, and population health focused specialty services; and chronic care management, transitions of care, and referral management services. The NeueSolutions segment enables providers and medical groups to succeed in performance-based arrangements; and participates in the centers for healthcare access to medicare beneficiaries. The company was formerly known as Bright Health Group, Inc. and changed its name to NeueHealth, Inc. in January 2024. NeueHealth, Inc. was incorporated in 2015 and is headquartered in Doral, Florida.

How the Company Makes Money

NeueHealth generates revenue through multiple streams, including subscription fees from healthcare providers for access to its digital health platform, transaction fees from telehealth consultations, and licensing fees for its data analytics tools. Additionally, the company may engage in strategic partnerships with healthcare organizations, insurance companies, and technology firms to expand its service offerings and reach. These collaborations can lead to revenue-sharing agreements, further enhancing its income potential. The increasing demand for telehealth services and digital health solutions, accelerated by the COVID-19 pandemic, has significantly contributed to NeueHealth's growth and revenue generation.

NeueHealth Inc Financial Statement Overview

Summary

NeueHealth Inc is facing significant financial challenges, including declining revenues, persistent losses, high leverage, and negative cash flows. The negative net profit margin and negative stockholders' equity indicate financial instability and risk.

Income Statement

NeueHealth Inc has experienced declining revenues and persistent net losses over the periods analyzed. The TTM (Trailing-Twelve-Months) data shows a negative net profit margin of -15.83%, indicating significant challenges in achieving profitability. The gross profit margin is 22.17%, which is relatively low for the industry, suggesting cost management issues. Revenue growth has been inconsistent, with a notable decline in recent periods.

Balance Sheet

The balance sheet reveals high leverage with a negative stockholders' equity of -$1.36 billion in the TTM period, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting a precarious financial position. These factors suggest significant financial instability and risk.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a TTM free cash flow of -$98.84 million. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its losses. This raises concerns about the company's ability to sustain operations without external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	936.66M	1.16B	751.16M	1.51B	514.89M
Gross Profit	194.52M	164.22M	88.19M	218.88M	62.97M
EBITDA	-80.76M	-566.80M	-246.39M	-308.58M	-249.31M
Net Income	-134.68M	-1.15B	-1.46B	-1.18B	-248.44M
Balance Sheet
Total Assets	544.38M	1.23B	4.67B	3.60B	1.81B
Cash, Cash Equivalents and Short-Term Investments	93.17M	93.56M	217.88M	433.76M	988.30M
Total Debt	204.61M	370.35M	303.95M	155.00M	28.42M
Total Liabilities	930.49M	1.48B	3.73B	2.32B	2.27B
Stockholders Equity	-434.69M	-343.53M	719.93M	1.15B	-503.67M
Cash Flow
Free Cash Flow	-125.55M	-2.73B	207.02M	51.65M	-63.71M
Operating Cash Flow	-123.22M	-2.73B	234.47M	82.06M	-57.24M
Investing Cash Flow	186.89M	1.12B	-429.72M	-552.89M	-689.74M
Financing Cash Flow	-253.55M	49.91M	1.07B	1.04B	712.44M

NeueHealth Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.72
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NEUE, the sentiment is Negative. The current price of 6.72 is below the 20-day moving average (MA) of 6.81, below the 50-day MA of 6.82, and above the 200-day MA of 6.45, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.63 is Neutral, neither overbought nor oversold. The STOCH value of 35.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NEUE.

NeueHealth Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CON	69 Neutral	$2.77B	18.53	18.79%	0.87%	―	―
CCLD	67 Neutral	$113.21M	―	22.69%	―	0.04%	98.87%
AVTX	56 Neutral	$117.45M	―	-90.25%	―	-45.35%	96.80%
HYPR	54 Neutral	$90.29M	―	-67.86%	―	0.34%	6.20%
Sector *	46 Neutral	C$193.30M	-2.83	-24.76%	3.14%	19.77%	0.53%
NEUE	45 Neutral	$60.64M	―	84.03%	―	-13.83%	87.09%
CBUS	39 Underperform	$72.14M	―	-157.73%	―	104.78%	40.41%

NeueHealth Inc Corporate Events

NeueHealth Inc Holds Annual Stockholders Meeting

On May 29, 2025, NeueHealth, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders elected ten directors to serve until the 2026 annual meeting, ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation for 2024 on a non-binding, advisory basis.

The most recent analyst rating on (NEUE) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on NeueHealth Inc stock, see the NEUE Stock Forecast page.